Blockade of Cell Volume Regulatory Protein NKCC1 Increases TMZ-Induced Glioma Apoptosis and Reduces Astrogliosis.
Animals
Antineoplastic Agents, Alkylating
Apoptosis
Biomarkers, Tumor
/ genetics
Cell Movement
Cell Proliferation
Cell Size
Female
Gene Expression Regulation, Neoplastic
/ drug effects
Glioma
/ drug therapy
Gliosis
/ genetics
Humans
Mice
Mice, Inbred C57BL
Prognosis
Solute Carrier Family 12, Member 2
/ genetics
Temozolomide
/ pharmacology
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
Journal
Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
19
09
2019
revised:
29
01
2020
accepted:
04
05
2020
pubmed:
13
5
2020
medline:
3
6
2021
entrez:
13
5
2020
Statut:
ppublish
Résumé
Glioma is one of the most common primary malignant tumors of the central nervous system accounting for approximately 40% of all intracranial tumors. Temozolomide is a conventional chemotherapy drug for adjuvant treatment of patients with high-risk gliomas, including grade II to grade IV. Our bioinformatic analysis of The Cancer Genome Atlas and Chinese Glioma Genome Atlas datasets and immunoblotting assay show that
Identifiants
pubmed: 32393472
pii: 1535-7163.MCT-19-0910
doi: 10.1158/1535-7163.MCT-19-0910
doi:
Substances chimiques
Antineoplastic Agents, Alkylating
0
Biomarkers, Tumor
0
SLC12A2 protein, human
0
Solute Carrier Family 12, Member 2
0
Temozolomide
YF1K15M17Y
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1550-1561Informations de copyright
©2020 American Association for Cancer Research.